Two Sigma Investments LP Makes New $4.09 Million Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Two Sigma Investments LP acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 38,675 shares of the medical equipment provider's stock, valued at approximately $4,085,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $473,000. KLCM Advisors Inc. bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $7,825,000. Van ECK Associates Corp raised its holdings in Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. MFG Wealth Management Inc. bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $1,506,000. Finally, Gries Financial LLC bought a new stake in Zimmer Biomet during the fourth quarter worth approximately $866,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZBH shares. Royal Bank of Canada dropped their target price on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. The Goldman Sachs Group dropped their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. JMP Securities dropped their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $111.53.

Zimmer Biomet Trading Down 1.1%

NYSE ZBH traded down $1.05 on Monday, hitting $91.12. 1,648,195 shares of the stock were exchanged, compared to its average volume of 1,799,587. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $116.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The company has a market capitalization of $18.03 billion, a price-to-earnings ratio of 20.48, a P/E/G ratio of 1.95 and a beta of 0.78. The company's 50-day moving average price is $99.60 and its two-hundred day moving average price is $104.59.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the company posted $1.94 EPS. The company's quarterly revenue was up 1.1% compared to the same quarter last year. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.05%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is currently owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.